Next Article in Journal
Steering the Clinical Translation of Delivery Systems for Drugs and Health Products
Previous Article in Journal
Imbalance of Drug Transporter-CYP450s Interplay by Diabetes and Its Clinical Significance
Previous Article in Special Issue
Polymeric Nanocarriers of Drug Delivery Systems in Cancer Therapy
 
 
Review

Recent Advances in Manufacturing Innovative Stents

1
Fraunhofer Institute for Ceramic Technologies and Systems IKTS, Maria-Reiche-Str. 2, 01109 Dresden, Germany
2
Balton Sp. z o.o. Modlińska 294, 03-152 Warsaw, Poland
3
VIP Technologies, Prospect Academicheskiy 8/2, 634055 Tomsk, Russia
4
Department of Science and Engineering of Oxide Materials, Faculty of Applied Chemistry and Materials Science, University Politehnica of Bucharest, Spl. Independentei 313, 060042 Bucharest, Romania
5
Department of Hydraulics, Hydraulic Machinery and Environmental Engineering, Faculty of Power Engineering, University Politehnica of Bucharest, Spl. Independentei 313, 060042 Bucharest, Romania
6
Academy of Romanian Scientists, Spl. Independentei 54, 050094 Bucharest, Romania
7
Research School of High-Energy Physics, Tomsk Polytechnic University, Lenin Avenue 30, 634050 Tomsk, Russia
*
Authors to whom correspondence should be addressed.
Pharmaceutics 2020, 12(4), 349; https://doi.org/10.3390/pharmaceutics12040349
Received: 22 February 2020 / Revised: 9 April 2020 / Accepted: 10 April 2020 / Published: 13 April 2020
Cardiovascular diseases are the most distributed cause of death worldwide. Stenting of arteries as a percutaneous transluminal angioplasty procedure became a promising minimally invasive therapy based on re-opening narrowed arteries by stent insertion. In order to improve and optimize this method, many research groups are focusing on designing new or improving existent stents. Since the beginning of the stent development in 1986, starting with bare-metal stents (BMS), these devices have been continuously enhanced by applying new materials, developing stent coatings based on inorganic and organic compounds including drugs, nanoparticles or biological components such as genes and cells, as well as adapting stent designs with different fabrication technologies. Drug eluting stents (DES) have been developed to overcome the main shortcomings of BMS or coated stents. Coatings are mainly applied to control biocompatibility, degradation rate, protein adsorption, and allow adequate endothelialization in order to ensure better clinical outcome of BMS, reducing restenosis and thrombosis. As coating materials (i) organic polymers: polyurethanes, poly(ε-caprolactone), styrene-b-isobutylene-b-styrene, polyhydroxybutyrates, poly(lactide-co-glycolide), and phosphoryl choline; (ii) biological components: vascular endothelial growth factor (VEGF) and anti-CD34 antibody and (iii) inorganic coatings: noble metals, wide class of oxides, nitrides, silicide and carbide, hydroxyapatite, diamond-like carbon, and others are used. DES were developed to reduce the tissue hyperplasia and in-stent restenosis utilizing antiproliferative substances like paclitaxel, limus (siro-, zotaro-, evero-, bio-, amphi-, tacro-limus), ABT-578, tyrphostin AGL-2043, genes, etc. The innovative solutions aim at overcoming the main limitations of the stent technology, such as in-stent restenosis and stent thrombosis, while maintaining the prime requirements on biocompatibility, biodegradability, and mechanical behavior. This paper provides an overview of the existing stent types, their functionality, materials, and manufacturing conditions demonstrating the still huge potential for the development of promising stent solutions. View Full-Text
Keywords: stent; stent coating; titanium oxynitride coating; drug-eluting stent; bioresorbable stent stent manufacturing stent; stent coating; titanium oxynitride coating; drug-eluting stent; bioresorbable stent stent manufacturing
Show Figures

Figure 1

MDPI and ACS Style

Beshchasna, N.; Saqib, M.; Kraskiewicz, H.; Wasyluk, Ł.; Kuzmin, O.; Duta, O.C.; Ficai, D.; Ghizdavet, Z.; Marin, A.; Ficai, A.; Sun, Z.; Pichugin, V.F.; Opitz, J.; Andronescu, E. Recent Advances in Manufacturing Innovative Stents. Pharmaceutics 2020, 12, 349. https://doi.org/10.3390/pharmaceutics12040349

AMA Style

Beshchasna N, Saqib M, Kraskiewicz H, Wasyluk Ł, Kuzmin O, Duta OC, Ficai D, Ghizdavet Z, Marin A, Ficai A, Sun Z, Pichugin VF, Opitz J, Andronescu E. Recent Advances in Manufacturing Innovative Stents. Pharmaceutics. 2020; 12(4):349. https://doi.org/10.3390/pharmaceutics12040349

Chicago/Turabian Style

Beshchasna, Natalia, Muhammad Saqib, Honorata Kraskiewicz, Łukasz Wasyluk, Oleg Kuzmin, Oana Cristina Duta, Denisa Ficai, Zeno Ghizdavet, Alexandru Marin, Anton Ficai, Zhilei Sun, Vladimir F. Pichugin, Joerg Opitz, and Ecaterina Andronescu. 2020. "Recent Advances in Manufacturing Innovative Stents" Pharmaceutics 12, no. 4: 349. https://doi.org/10.3390/pharmaceutics12040349

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop